ELAVL4 promotes the tumorigenesis of small cell lung cancer by stabilizing LncRNA LYPLAL1‐DT and enhancing profilin 2 activation
The FASEB Journal · 2023
DOI: 10.1096/fj.202300314rr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Shuxin Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research, Beijing, P.R. China. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Small Cell Lung Carcinoma, Lung Neoplasms, MicroRNAs. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Small cell lung cancer (SCLC) is one of the most malignant tumors that has an extremely poor prognosis. RNA‐binding protein (RBP) and long noncoding RNA (lncRNA) have been shown to be key regulators during tumorigenesis as well as lung tumor progression. However, the role of RBP ELAVL4 and lncRNA LYPLAL1‐DT in SCLC remains unclear. In this study, we verified that lncRNA LYPLAL1‐DT acts as an SCLC oncogenic lncRNA and was confirmed in vitro and in vivo. Mechanistically , LYPLAL1‐DT negatively regulates the expression of miR‐204‐5p, leading to the upregulation of PFN2, thus, promoting SCLC cell proliferation, migration, and invasion. ELAVL4 has been shown to enhance the stability of LYPLAL1‐DT and PFN2 mRNA. Our study reveals a regulatory pathway, where ELAVL4 stabilizes PFN2 and LYPLAL1‐DT with the latter further increasing PFN2 expression by blocking the action of miR‐204‐5p. Upregulated PFN2 ultimately promotes tumorigenesis and invasion in SCLC. These findings provide novel prognostic indicators as well as promising new therapeutic targets for SCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Basic Medical Sciences, Capital Medical University, Beijing Key Laboratory of Cancer Invasion & Metastasis Research, Beijing, P.R. China.
- Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS); and Comparative Medicine Center, Peking Union Medical College (PUMC), Beijing, China.
- Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
ORCID-Profile: Shuxin Li, Jianyi Lv, Xing Zhang, Qiuyu Zhang, Zhihui Li, Jing Lu, Xueyun Huo, Meng Guo, Xin Liu, Ran Gao, Jianan Gong, Changlong Li, Weiying Li, Tongmei Zhang, Jinghui Wang, Zhenwen Chen, Xiaoyan Du
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, S., Lv, J., Zhang, X., Zhang, Q., Li, Z., Lu, J., Huo, X., Guo, M., Liu, X., Gao, R., Gong, J., Li, C., Li, W., Zhang, T., Wang, J., Chen, Z., & Du, X. (2023). ELAVL4 promotes the tumorigenesis of small cell lung cancer by stabilizing LncRNA LYPLAL1‐DT and enhancing profilin 2 activation. The FASEB Journal. https://doi.org/10.1096/fj.202300314rr
Vancouver
Li S, Lv J, Zhang X, Zhang Q, Li Z, Lu J, et al. ELAVL4 promotes the tumorigenesis of small cell lung cancer by stabilizing LncRNA LYPLAL1‐DT and enhancing profilin 2 activation. The FASEB Journal. 2023. doi:10.1096/fj.202300314rr
BibTeX
@article{Li2023,
author = {Li, Shuxin and Lv, Jianyi and Zhang, Xing and Zhang, Qiuyu and Li, Zhihui and Lu, Jing and Huo, Xueyun and Guo, Meng and Liu, Xin and Gao, Ran and Gong, Jianan and Li, Changlong and Li, Weiying and Zhang, Tongmei and Wang, Jinghui and Chen, Zhenwen and Du, Xiaoyan},
title = {ELAVL4 promotes the tumorigenesis of small cell lung cancer by stabilizing LncRNA LYPLAL1‐DT and enhancing profilin 2 activation},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202300314rr}
}
EUVIMED